Featured Research

from universities, journals, and other organizations

Potential drug target has key role in the heart

Date:
June 1, 2010
Source:
Journal of Clinical Investigation
Summary:
Inhibitors of GSK-3 proteins are being developed as potential therapeutics for numerous conditions, including bipolar disorder, Alzheimer's disease, and diabetes. However, new research in mice indicates that these drugs might have adverse effects on the heart, suggesting that the risk/benefit assessment of such drugs might need to be considered carefully.

Inhibitors of GSK-3 proteins are being developed as potential therapeutics for numerous conditions, including bipolar disorder, Alzheimer disease, and diabetes. However, a team of researchers, led by Thomas Force, at Thomas Jefferson University, Philadelphia, has generated data in mice that indicate that these drugs might have adverse effects on the heart, suggesting that the risk/benefit assessment of such drugs might need to be considered carefully.

Related Articles


In the study, mice lacking GSK-3-alpha were found to develop heart defects when they were analyzed at over 2 months of age. In particular, they had enlarged heart muscle cells and hearts, and their hearts showed an inability to contract optimally. Further, in a model of high blood pressure, which puts substantial stress on the heart, mice lacking GSK-3-alpha developed much more severe heart defects than did normal mice.

These and other data generated in the study lead the authors to conclude that in the absence of GSK-3-alpha, the mouse heart cannot respond effectively to high blood pressure and rapidly fails, raising concern that therapeutic GSK-3 inhibitors might have serious adverse effects.

The research appears in the Journal of Clinical Investigation.


Story Source:

The above story is based on materials provided by Journal of Clinical Investigation. Note: Materials may be edited for content and length.


Journal Reference:

  1. Jibin Zhou, Hind Lal, Xiongwen Chen, Xiying Shang, Jianliang Song, Yingxin Li, Risto Kerkela, Bradley W. Doble, Katrina MacAulay, Morgan DeCaul, Walter J. Koch, John Farber, James Woodgett, Erhe Gao and Thomas Force. GSK-3-alpha directly regulates beta-adrenergic signaling and the response of the heart to hemodynamic stress in mice. Journal of Clinical Investigation, 2010; DOI: 10.1172/JCI41407

Cite This Page:

Journal of Clinical Investigation. "Potential drug target has key role in the heart." ScienceDaily. ScienceDaily, 1 June 2010. <www.sciencedaily.com/releases/2010/06/100601124119.htm>.
Journal of Clinical Investigation. (2010, June 1). Potential drug target has key role in the heart. ScienceDaily. Retrieved March 6, 2015 from www.sciencedaily.com/releases/2010/06/100601124119.htm
Journal of Clinical Investigation. "Potential drug target has key role in the heart." ScienceDaily. www.sciencedaily.com/releases/2010/06/100601124119.htm (accessed March 6, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, March 6, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Bupa Eyes India Healthcare Opportunities

Bupa Eyes India Healthcare Opportunities

Reuters - Business Video Online (Mar. 5, 2015) Bupa is hoping to expand in India&apos;s fast-growing health insurance market, once a rule change on foreign investment is implemented. The British private healthcare group&apos;s CEO tells Grace Pascoe why it&apos;s so keen on the new opportunity. Video provided by Reuters
Powered by NewsLook.com
Doctor in Your Pocket Is Getting Smarter

Doctor in Your Pocket Is Getting Smarter

Reuters - Business Video Online (Mar. 5, 2015) Mobile apps are turning smartphones into a personal doctors, with users able to measure heart rate, blood pressure and even blood sugar. But will it change our behaviour? Ivor Bennett reports from the Mobile World Congress in Barcelona. Video provided by Reuters
Powered by NewsLook.com
AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

Newsy (Mar. 5, 2015) AbbVie announced Wednesday it will buy cancer drugmaker Pharmacyclics in a $21 billion deal. Video provided by Newsy
Powered by NewsLook.com
Toddlers Drinking Coffee? Why You Shouldn't Share Your Joe

Toddlers Drinking Coffee? Why You Shouldn't Share Your Joe

Newsy (Mar. 5, 2015) A survey of Boston mothers and toddlers found that 15 percent of two-year-olds drink coffee and 2.5 percent of 1-year-olds. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins